Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or ...

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

The research-ready Virtual Registry was built as part of the Helix Research Network (HRN). The cohort consists of whole Exome+® sequencing profiles for 15,000 GLP-1 agonist treat ...

Ferrotec Holdings Corporation today announced that it has earned a Supplier Excellence Award from Applied Materials, Inc., the leader in materials engineering solutions used to produce virtually every ...

Applause, the world leader in digital quality and crowd-sourced testing, today announced another milestone year, surpassing $200 million in Annual Recurring Revenue (ARR). Building on its unparalleled ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...